FR2984129B1 - Utilisation de la proteine mmp-12 dans la prevention et/ou le traitement des etats pelliculaires du cuir chevelu - Google Patents

Utilisation de la proteine mmp-12 dans la prevention et/ou le traitement des etats pelliculaires du cuir chevelu

Info

Publication number
FR2984129B1
FR2984129B1 FR1161621A FR1161621A FR2984129B1 FR 2984129 B1 FR2984129 B1 FR 2984129B1 FR 1161621 A FR1161621 A FR 1161621A FR 1161621 A FR1161621 A FR 1161621A FR 2984129 B1 FR2984129 B1 FR 2984129B1
Authority
FR
France
Prior art keywords
scalp
prevention
treatment
polypeptide
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1161621A
Other languages
English (en)
Other versions
FR2984129A1 (fr
Inventor
Audrey Gueniche
Isabelle Castiel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LOreal SA
Original Assignee
LOreal SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LOreal SA filed Critical LOreal SA
Priority to FR1161621A priority Critical patent/FR2984129B1/fr
Priority to PCT/IB2012/057242 priority patent/WO2013088371A2/fr
Publication of FR2984129A1 publication Critical patent/FR2984129A1/fr
Application granted granted Critical
Publication of FR2984129B1 publication Critical patent/FR2984129B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/006—Antidandruff preparations
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24065—Macrophage elastase (3.4.24.65), i.e. metalloelastase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Birds (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)

Abstract

La présente invention concerne l'utilisation cosmétique d'une quantité efficace d'au moins un actif consistant en un polypeptide ayant au moins 80 % d'identité en acides aminés avec une métalloprotéinase MMP-12 de séquence choisie parmi SEQ ID NO: 1, SEQ ID NO: 2 et SEQ ID NO: 3, ou un fragment C-terminal dudit polypeptide, pour prévenir et/ou traiter les états pelliculaires du cuir chevelu, ledit polypeptide ou ledit fragment comprenant la séquence KDXK, dans laquelle X représente l'acide aspartique ou l'acide glutamique
FR1161621A 2011-12-14 2011-12-14 Utilisation de la proteine mmp-12 dans la prevention et/ou le traitement des etats pelliculaires du cuir chevelu Active FR2984129B1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
FR1161621A FR2984129B1 (fr) 2011-12-14 2011-12-14 Utilisation de la proteine mmp-12 dans la prevention et/ou le traitement des etats pelliculaires du cuir chevelu
PCT/IB2012/057242 WO2013088371A2 (fr) 2011-12-14 2012-12-12 Utilisation de la protéine mmp-12 dans la prévention et/ou le traitement d'états pélliculaires du cuir chevelu

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1161621A FR2984129B1 (fr) 2011-12-14 2011-12-14 Utilisation de la proteine mmp-12 dans la prevention et/ou le traitement des etats pelliculaires du cuir chevelu

Publications (2)

Publication Number Publication Date
FR2984129A1 FR2984129A1 (fr) 2013-06-21
FR2984129B1 true FR2984129B1 (fr) 2014-01-10

Family

ID=45926673

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1161621A Active FR2984129B1 (fr) 2011-12-14 2011-12-14 Utilisation de la proteine mmp-12 dans la prevention et/ou le traitement des etats pelliculaires du cuir chevelu

Country Status (2)

Country Link
FR (1) FR2984129B1 (fr)
WO (1) WO2013088371A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6997222B2 (ja) 2017-06-23 2022-01-17 ザ プロクター アンド ギャンブル カンパニー 皮膚の外観を改善するための組成物及び方法
EP3817717A1 (fr) 2018-07-03 2021-05-12 The Procter & Gamble Company Méthode de traitement d'une affection cutanée
EP4157206A1 (fr) 2020-06-01 2023-04-05 The Procter & Gamble Company Méthode d'amélioration de la pénétration d'un composé de vitamine b3 dans la peau
US10959933B1 (en) 2020-06-01 2021-03-30 The Procter & Gamble Company Low pH skin care composition and methods of using the same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030235577A1 (en) * 2002-04-08 2003-12-25 Shapiro Steven D. Methods and compositions for preventing and treating microbial infections
DE10324567A1 (de) 2003-05-30 2004-12-23 Symrise Gmbh & Co. Kg Verwendung von Diphenylmethan-Derivaten als antimikrobielle Wirkstoffe
TWI395593B (zh) * 2008-03-06 2013-05-11 Halozyme Inc 可活化的基質降解酵素之活體內暫時性控制

Also Published As

Publication number Publication date
FR2984129A1 (fr) 2013-06-21
WO2013088371A3 (fr) 2013-12-27
WO2013088371A2 (fr) 2013-06-20

Similar Documents

Publication Publication Date Title
MA38144A1 (fr) Compositions et procédés pour le traitement de protéinopathies
RU2498988C2 (ru) Ингибиторы активности протеинтирозинкиназы
EA201000441A1 (ru) Водные офтальмологические препараты
EA200971053A1 (ru) Способы лечения кожных язв
BR112012018246A2 (pt) compostos de amida reversa como inibidores de proteína desacetilase e métodos de uso destes
CO6230997A2 (es) Proteinas de union a antigeno contra proproteina convertasa subtilisina/kexina tipo 9 (pcsk9)
MA31862B1 (fr) Anticorps anti-mésothéline et leurs utilisations
ATE489957T1 (de) Mittel zur behandlung von entzündlichen erkrankungen
HRP20110242T1 (hr) Formulacija s fuzijskim proteinom glp-1-fc
MA41759A (fr) Inclusion de l'exon 2, induite par antisens, dans une alpha-glucosidase acide
FR2984129B1 (fr) Utilisation de la proteine mmp-12 dans la prevention et/ou le traitement des etats pelliculaires du cuir chevelu
WO2011094545A3 (fr) Compositions et procédés pour améliorer l'activité des protéasomes
JP2013542919A5 (fr)
BR112012019924A2 (pt) polipeptídeos de ligação de agonista de dr5.
EA201200515A1 (ru) Полипептиды и их применение
EA202190310A1 (ru) Белок для лечения воспалительных заболеваний
WO2019045248A3 (fr) Peptide présentant une activité d'atténuation des rides et utilisations associées
EA202190888A1 (ru) Пептид для применения в косметике
MX2021006253A (es) Terapias génicas para enfermedad neurodegenerativa.
EA201300062A1 (ru) Фармацевтическая композиция, предназначенная для лечения заболеваний центральной и периферической нервной системы сосудистого, травматического, токсического, гипоксического и аутоиммунного генеза
WO2010036813A8 (fr) Composes et methodes de prevention ou de traitement des affections neurodegeneratives associees a une accumulation de peptides abeta
FR2942720B1 (fr) Utilisation cosmetique d'hesperidine.
WO2008117730A1 (fr) Composition pour empêcher ou traiter une maladie pulmonaire
EA202090802A1 (ru) Пептидная композиция для лечения повреждений, связанных с возбуждающей нейротоксичностью
MA49396A (fr) Traitement de la migraine avec acétyl-leucine

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7

PLFP Fee payment

Year of fee payment: 9

PLFP Fee payment

Year of fee payment: 10

PLFP Fee payment

Year of fee payment: 11

PLFP Fee payment

Year of fee payment: 12

PLFP Fee payment

Year of fee payment: 13